vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and TaoWeave, Inc. (TWAV). Click either name above to swap in a different company.
Applied Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $622.0K, roughly 1.6× TaoWeave, Inc.). TaoWeave, Inc. runs the higher net margin — -448.2% vs -1899.0%, a 1450.8% gap on every dollar of revenue. On growth, Applied Therapeutics, Inc. posted the faster year-over-year revenue change (719.7% vs 10.5%).
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
APLT vs TWAV — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $622.0K |
| Net Profit | $-19.0M | $-2.8M |
| Gross Margin | — | 47.1% |
| Operating Margin | -1675.8% | -126.4% |
| Net Margin | -1899.0% | -448.2% |
| Revenue YoY | 719.7% | 10.5% |
| Net Profit YoY | 72.3% | -215.4% |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0K | ||
| Q3 25 | $1.0M | $601.0K | ||
| Q2 25 | $0 | $592.0K | ||
| Q1 25 | $0 | $622.0K | ||
| Q4 24 | $-1.0K | $563.0K | ||
| Q3 24 | — | $578.0K | ||
| Q2 24 | $144.0K | $611.0K | ||
| Q1 24 | $190.0K | $626.0K |
| Q4 25 | — | $-2.8M | ||
| Q3 25 | $-19.0M | $-2.3M | ||
| Q2 25 | $-21.3M | $-605.0K | ||
| Q1 25 | $-21.8M | $-672.0K | ||
| Q4 24 | $44.0M | $-884.0K | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | $2.9M | $-983.0K | ||
| Q1 24 | $-83.9M | $-1.1M |
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | -0.5% |
| Q4 25 | — | -126.4% | ||
| Q3 25 | -1675.8% | -133.4% | ||
| Q2 25 | — | -115.4% | ||
| Q1 25 | — | -111.1% | ||
| Q4 24 | 3302300.0% | -164.8% | ||
| Q3 24 | — | -185.5% | ||
| Q2 24 | -14194.4% | -166.6% | ||
| Q1 24 | -11101.6% | -189.1% |
| Q4 25 | — | -448.2% | ||
| Q3 25 | -1899.0% | -381.0% | ||
| Q2 25 | — | -102.2% | ||
| Q1 25 | — | -108.0% | ||
| Q4 24 | -4400700.0% | -157.0% | ||
| Q3 24 | — | -179.9% | ||
| Q2 24 | 2012.5% | -160.9% | ||
| Q1 24 | -44177.9% | -181.5% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $0.52 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.67 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-561.0K | $7.0M |
| Total Assets | $34.4M | $8.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3M | ||
| Q3 25 | $11.9M | $3.7M | ||
| Q2 25 | $30.4M | $10.8M | ||
| Q1 25 | $50.8M | $4.3M | ||
| Q4 24 | $79.4M | $5.0M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | $122.2M | $5.9M | ||
| Q1 24 | $146.5M | — |
| Q4 25 | — | $7.0M | ||
| Q3 25 | $-561.0K | $9.8M | ||
| Q2 25 | $17.4M | $11.3M | ||
| Q1 25 | $36.7M | $3.4M | ||
| Q4 24 | $57.0M | $4.0M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | $72.4M | $5.1M | ||
| Q1 24 | $67.3M | $4.4M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | $34.4M | $10.9M | ||
| Q2 25 | $37.3M | $13.1M | ||
| Q1 25 | $56.9M | $4.8M | ||
| Q4 24 | $86.7M | $5.3M | ||
| Q3 24 | — | $6.0M | ||
| Q2 24 | $127.8M | $6.3M | ||
| Q1 24 | $151.2M | $5.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-744.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-744.0K | ||
| Q3 25 | $-18.4M | $-1.6M | ||
| Q2 25 | $-20.3M | $-37.0K | ||
| Q1 25 | $-28.6M | $-680.0K | ||
| Q4 24 | $-19.5M | $-255.0K | ||
| Q3 24 | — | $-911.0K | ||
| Q2 24 | $-22.6M | $-1.6M | ||
| Q1 24 | $-18.9M | $-630.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
